Extrawell Pharmaceutical Holdings Limited

SEHK:858 Voorraadrapport

Marktkapitalisatie: HK$126.7m

Extrawell Pharmaceutical Holdings Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Yi Xie

Algemeen directeur

HK$1.4m

Totale compensatie

Percentage CEO-salaris94.9%
Dienstverband CEO10.9yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuur13.5yrs

Recente managementupdates

Recent updates

Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt

Mar 18
Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt

Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt

Dec 01
Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt

We Think That There Are Some Issues For Extrawell Pharmaceutical Holdings (HKG:858) Beyond Its Promising Earnings

Aug 04
We Think That There Are Some Issues For Extrawell Pharmaceutical Holdings (HKG:858) Beyond Its Promising Earnings

Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?

Mar 15
Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?

Some Shareholders May Object To A Pay Rise For Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO This Year

Aug 20
Some Shareholders May Object To A Pay Rise For Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO This Year

Analyse CEO-vergoeding

Hoe is Yi Xie's beloning veranderd ten opzichte van Extrawell Pharmaceutical Holdings's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Mar 31 2024HK$1mHK$1m

-HK$163m

Dec 31 2023n/an/a

-HK$159m

Sep 30 2023n/an/a

-HK$154m

Jun 30 2023n/an/a

-HK$13m

Mar 31 2023HK$1mHK$1m

HK$129m

Dec 31 2022n/an/a

HK$109m

Sep 30 2022n/an/a

HK$88m

Jun 30 2022n/an/a

HK$109m

Mar 31 2022HK$1mHK$1m

HK$131m

Dec 31 2021n/an/a

HK$12m

Sep 30 2021n/an/a

-HK$107m

Jun 30 2021n/an/a

-HK$114m

Mar 31 2021HK$1mHK$1m

-HK$121m

Dec 31 2020n/an/a

HK$6m

Sep 30 2020n/an/a

HK$133m

Jun 30 2020n/an/a

HK$108m

Mar 31 2020HK$1mHK$1m

HK$83m

Dec 31 2019n/an/a

HK$73m

Sep 30 2019n/an/a

HK$63m

Jun 30 2019n/an/a

HK$63m

Mar 31 2019HK$1mHK$1m

HK$64m

Dec 31 2018n/an/a

HK$51m

Sep 30 2018n/an/a

HK$39m

Jun 30 2018n/an/a

HK$34m

Mar 31 2018HK$1mHK$1m

HK$30m

Compensatie versus markt: De totale vergoeding ($USD 178.11K ) Yi } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 232.99K ).

Compensatie versus inkomsten: De vergoeding van Yi is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Yi Xie (61 yo)

10.9yrs

Tenure

HK$1,386,000

Compensatie

Dr. Yi Xie, Ph.D. serves as the Chief Executive Officer of Extrawell Pharmaceutical Holdings Ltd. Dr. Xie is one of the founders of United Gene group of companies in the PRC. Dr. Xie is responsible for res...

Bestuursleden

NaamPositieTenureCompensatieEigendom
Yi Xie
Executive Chairman & CEO10.9yrsHK$1.39mgeen gegevens
Yi Lou
Executive Director16.1yrsHK$557.00kgeen gegevens
Yong Cheng
Deputy CEO & Executive Director10.9yrsHK$713.00k6.14%
HK$ 7.8m
Yi Guo
Executive Director1.6yrsgeen gegevensgeen gegevens
Sau Kuen Wong
Company Secretary & Executive Director16.1yrsHK$940.00kgeen gegevens
Yumin Mao
Honorary Chairman and Chief Scientific Advisorno datageen gegevens7.95%
HK$ 10.1m
Lin Hu Fang
Independent Non-Executive Director23.8yrsHK$70.00kgeen gegevens
Song Jin
Independent Non-Executive Director20.2yrsHK$70.00kgeen gegevens
Li Zeng
Independent Non-Executive Directorless than a yeargeen gegevensgeen gegevens

13.5yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 858 zijn ervaren en ervaren (gemiddelde ambtstermijn van 13.5 jaar).